PALM BEACH, Fla., Feb. 2, 2022 /PRNewswire/ FinancialNewsMedia.com News Commentary - In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical.
/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing.
/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing.